An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 1-2, 2004, Pages 8-13

  Arakawa, Kenji ^a   Ishihara, Tomomi ^a   Aoto, Masamichi ^a   Inamasu, Masanori ^a   Kitamura, Kazuyuki ^a   Saito, Akira ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Antidiabetic; Cardiac hypertrophy; Insulin resistance; T 174; Thiazolidinedione; Volume overload

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [2 (2 NAPHTHYLMETHYL) 5 BENZOXAZOLYLMETHYL] 2,4 THIAZOLIDINEDIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD VOLUME; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SCREENING; FEMALE; HEART EDEMA; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE VARIABILITY; HEART RIGHT ATRIUM PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE WALL; HEART VOLUME; HEART WEIGHT; HEMATOCRIT; MORPHOMETRICS; NONHUMAN; PLASMA VOLUME; RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOMEGALY; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HEART; HEART RATE; HYPOGLYCEMIC AGENTS; INSULIN; MYOCARDIUM; ORGAN SIZE; PLASMA VOLUME; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 1242337440     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.03954.x     Document Type: Article

References (41)

1. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9.
2. Schoonjans K, Auwerx J. Thiazolidinediones: An update. Lancet 2000; 355: 1008-10.
3. Lehmann JM, Moore LB, Smith Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 1995; 270: 12 953-6.
4. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J. Clin. Invest. 2000; 106: 467-72.
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-58.
6. Ikeda H, Taketomi S, Sugiyama Y et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 1990; 40: 156-62.
7. Arakawa K, Ishihara T, Aoto M, Inamasu M, Saito A, Ikezawa K. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br. J. Pharmacol. 1998; 125: 429-36.
8. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 1998; 338: 916-17.
9. Wise J. Diabetes drug withdrawn after reports of hepatic events. BMJ 1997; 315; 1564.
10. Kato NS, Wang JL, Ergun ME, Meehan WP. Thyroxine (T3) and pioglitazone induces cardiac hypertrophy via different mechanisms. J. Mol. Cell. Cardiol. 1995; 27: A111 (Abstract).
11. Kato NS, Wang JL, Meehan WP, Ergun ME. Pioglitazone causes differential gene expression in rat heart. J. Mol. Cell. Cardiol. 1995; 27: A57 (Abstract).
12. Williams GD, Deldar A, Jordan WH, Gries C, Long GG, Dimarchi RD. Subchronic toxicity of the thiazolidinedione, Tanabe-174 (LY282449), in the rat and dog. Diabetes 1993; 42 (Suppl. 1): 59A (Abstract).
13. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JP. Therapeutic index for rosiglitazone in dietary obese rats: Separation of efficacy and haemodilution. Br. J. Pharmacol. 1999; 128: 1570-6.
14. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997; 5: 294-313.
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
16. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
17. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339: 229-34.
18. Katz AM. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N. Engl. J. Med. 1990; 322: 100-10.
19. Rothwell C, McGuire EJ, Altrogge DM, Masuda H, de la Iglesia FA. Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J. Toxicol. Sci. 2002; 27: 35-47.
20. Aleo MD, Lundeen GR, Blackwell DK et al. Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-γ agonist. J. Pharmacol. Exp. Ther. 2003; 305: 1173-82.
21. Lebovitz HE. Differentiating members of the thiazolidinedione class. A focus on safety. Diabetes Metab. Res. Rev. 2002; 18 (Suppl. 2): S23-9.
22. Arakawa K, Inamasu M, Matsumoto M et al. Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships. Chem. Pharm. Bull 1997; 45: 1984-93.
23. Mizukami J, Taniguchi T. The antidiabetic agent thiazolidinedione stimulates the interaction between PPARγ and CBP. Biochem. Biophys. Res. Commun. 1997; 240: 61-4.
24. Yamauchi-Kohno R, Miyauchi T, Hoshino T et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters. Increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 1999; 99: 2171-6.
25. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22: 924-9.
26. Bressler R, Gay R, Copeland JG, Bahl JJ, Bedotto J, Goldman S. Chronic inhibition of fatty acid oxidation: New model of diastolic dysfunction. Life Sci. 1989; 44: 1897-906.
27. Litwin SE, Raya TE, Gay RG et al. Chronic inhibition of fatty acid oxidation: New model of diastolic dysfunction. Am. J. Physiol. 1990; 258: H51-6.
28. Rupp H, Elimban V, Dhalla NS. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyl-transferase I inhibitor. FASEB J. 1992; 6: 2349-53.
29. Cook GA, Otto DA, Cornell NW. Differential inhibition of ketogenesis by malonyl-CoA in mitochondria from fed and starved rats. Biochem. J. 1980; 192: 955-8.
30. Lee SM, Bahl JJ, Bressler R. Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/db). Biochem. Med. 1985; 33: 104-9.
31. Sage SW, Buevalleskey J, Burkhart D, Stephens TW. Inhibition of long chain fatty acid oxidation is not involved in thiazolidinedione induced cardiac hypertrophy. Diabetes 1994; 43 (Suppl. 1): A221 (Abstract).
32. Young MMR, Squassante L, Werner J. Troglitazone has no effect on the red cell mass or other erythropoietic parameters. Diabetologia 1997; 40 (Suppl. 1): A311 (Abstract).
33. Lundin S, Friberg P, Ricksten SE. Diastolic properties of the hypertrophied left ventricle in spontaneously hypertensive rats. Acta Physiol. Scand. 1983; 118: 1-9.
34. Tsoporis J, Yuan BX, Leenen FH. Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats. Am. J. Physiol. 1989; 256: H876-80.
35. Grossman W. Cardiac hypertrophy: Useful adaptation or pathologic process? Am. J. Med. 1980; 69: 576-84.
36. Gerdes AM, Campbell SE, Hilbelink DR. Structural remodeling of cardiac myocytes in rats with arteriovenous fistulas. Lab. Invest. 1988; 59: 857-61.
37. Yoshioka S, Nishino H, Shiraki T et al. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993; 42: 75-80.
38. Buchanan TA, Meehan WP, Jeng YY et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 1995; 96: 354-60.
39. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 1995; 8: 316-20.
40. Chang CH, McNamara LA, Berman C et al. Effect of in vivo PPARγ activation on plasma volume and cardiovascular function in rats. Diabetes 2002; 51 (Suppl. 2): A137 (Abstract).
41. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N. Engl. J. Med. 2002; 347: 1342-9.